1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  05/20 04:00:00 pm EDT
136.25 USD   -4.97%
05/19EU health regulator backs using AstraZeneca COVID shot as booster
RE
05/18Moderna Seeks Swissmedic Nod For COVID-19 Shot In Children Aged Six Months To Five years
MT
05/18As COVID cases rise, U.S. health officials mull widening additional booster eligibility
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EU regulator says mRNA COVID-19 shots do not complicate pregnancies

01/18/2022 | 09:16am EDT

Jan 18 (Reuters) - A review by the European Union's drug regulator found that mRNA COVID-19 vaccines do not cause pregnancy complications for expectant mothers and their babies, after it assessed data from studies involving around 65,000 pregnancies at different stages.

The European Medicines Agency said on Tuesday the review conducted by its COVID-19 task force also found that COVID-19 shots are as effective at cutting the risk of hospitalisation and death in pregnant people as in non-pregnant people. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Ramakrishnan M.)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. -4.97% 136.25 Delayed Quote.-46.35%
ON SEMICONDUCTOR CORPORATION 0.70% 56.46 Delayed Quote.-16.87%
All news about MODERNA, INC.
05/19EU health regulator backs using AstraZeneca COVID shot as booster
RE
05/18Moderna Seeks Swissmedic Nod For COVID-19 Shot In Children Aged Six Months To Five year..
MT
05/18As COVID cases rise, U.S. health officials mull widening additional booster eligibility
RE
05/18Moderna, International AIDS Vaccine Initiative to Start Volunteer Screening for Phase 1..
MT
05/18Piper Sandler Adjusts Moderna's Price Target to $214 From $348, Reiterates Overweight R..
MT
05/18From storage to transport, hurdles to getting COVID vaccine to N.Koreans
RE
05/17TRANSCRIPT : Moderna, Inc. - Special Call
CI
05/17FDA Expands Authorization of Pfizer Covid Booster to Kids 5 to 11
DJ
05/13MODERNA, INC. Change in Directors or Principal Officers, Financial Statements and Exhi..
AQ
05/13SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 22 022 M - -
Net income 2022 11 474 M - -
Net cash 2022 18 081 M - -
P/E ratio 2022 5,01x
Yield 2022 -
Capitalization 54 195 M 54 195 M -
EV / Sales 2022 1,64x
EV / Sales 2023 3,29x
Nbr of Employees 2 700
Free-Float 90,6%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 136,25 $
Average target price 216,12 $
Spread / Average Target 58,6%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567
ALNYLAM PHARMACEUTICALS, INC.-23.72%15 980